SAN DIEGO, March 28, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences:
Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days
Tuesday, April 4, 2023, at 3:55 p.m. ET
BofA Securities 2023 Health Care Conference
Wednesday, May 10, 2023, at 3:40 p.m. PT
Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations. Replays will be available for up to 30 days following each event.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
Media: Nivi Nehra Vice President, Corporate Communications 888-969-7879 This email address is being protected from spambots. You need JavaScript enabled to view it. | Investors: Naomi Eichenbaum Vice President, Investor Relations 888-969-7879 This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$6.55 |
Daily Change: | 0.29 4.63 |
Daily Volume: | 1,339,384 |
Market Cap: | US$498.520M |
April 24, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB